NEW YORK (GenomeWeb News) – BioMérieux and Quanterix announced today a deal granting BioMérieux worldwide exclusive rights to Quanterix's Single Molecule Array (SiMoA) technology in clinical laboratories and for industrial applications.

BioMérieux also took an initial $15 million stake in the Lexington, Mass.-based diagnostics firm as part of an $18.5 million Series C financing round announced by Quanterix today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.